about
The role of PET/CT in the evaluation of patients affected by limbic encephalitis: A systematic review of the literature.PET Neuroimaging: Insights on Dystonia and Tourette Syndrome and Potential ApplicationsFDG-PET/CT predicts outcome in oropharingeal carcinoma patients undergoing intensity modulated radiation therapy with dose escalation to FDG-avid tumour volumes.18F-FDG PET reveals unique features of large vessel inflammation in patients with Takayasu's arteritis.Role of molecular imaging in the management of patients affected by inflammatory bowel disease: State-of-the-art.Neuropsychological and FDG-PET profiles in VGKC autoimmune limbic encephalitis.Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT.Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - a multicenter experience.Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC).Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT.Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid.Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma.Whole body magnetic resonance in indolent lymphomas under watchful waiting: The time is now.Evaluation of an optimized [18 F]fluoro-deoxy-glucose positron emission tomography voxel-wise method to early support differential diagnosis in atypical Parkinsonian disorders.18F-fluoroethylcholine (18F-Cho) PET/MRI functional parameters in pediatric astrocytic brain tumors.Radiotracers for amyloid imaging in neurodegenerative disease: state-of-the-art and novel concepts.18F-FDG PET/CT for Early Postradiotherapy Assessment in Solitary Bone Plasmacytomas.Reply to letter of Adams and Kwee: Critical considerations on the predictive value of end-of-treatment FDG/PET in lymphoma.Radiation Treatment of Lymph Node Recurrence from Prostate Cancer: Is 11C-Choline PET/CT Predictive of Survival Outcomes?Correction to: Predictive and prognostic value of F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroidImaging features of adrenal massesClinical and prognostic value of 18F-FDG-PET/CT in restaging of pancreatic cancerPET Evaluation of Late Cerebral Effect in Advanced Radiation Therapy Techniques for Cranial Base TumorsLetter to the Editor Regarding "The Radiological Imaging Features of Easily Misdiagnosed Epithelioid Glioblastoma in Seven Patients"18F-Facbc in Prostate Cancer: A Systematic Review and Meta-AnalysisTheragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future ApplicationsPrefrontal Cortical Stimulation in Tourette Disorder: Proof-of-concept Clinical and Neuroimaging Study68Ga-dotatoc vs. 18F-FDG vs. radiolabelled PSMA PET/CT in renal cancer patientsClinical and Prognostic Value of 18F-FDG-PET/CT in the Restaging Process of Recurrent Cutaneous MelanomaCholine-PET/CT in the Differential Diagnosis Between Cystic Glioblastoma and Intraparenchymal Hemorrhage18F-Florbetaben PET/CT to Assess Alzheimer's Disease: A new Analysis Method for Regional Amyloid QuantificationPositron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 1Potential clinical value of quantitative fluorine-18-fluorodeoxyglucose-PET/computed tomography using a graph-based method analysis in evaluation of incidental lesions of gastrointestinal tract: correlation with endoscopic and histopathological findPrognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter studyPositron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2
P50
Q30961423-9B179E2C-9A7A-47BD-9545-2D713CA281C6Q34442368-9CC7B085-5A8F-41A2-9322-AA1305170C79Q38729923-473DBB78-F2FE-49A0-96C1-959B9D6B94CFQ38970688-94E90383-BD2A-4873-B7FA-48DA959A2AB5Q39008712-67DED9C4-0488-44C8-8978-E234693F85A5Q39449370-4F23AA2F-96F9-479E-8143-646496B03B4DQ39450381-FEE00333-753A-44F1-8AC7-863D423B8D84Q40527607-B0790135-BEAC-482C-837A-513612EE0E15Q40723551-49667B1E-6D82-4FB6-90DD-BE98F9572DB7Q40765432-21E413B5-D8EA-40F1-B1F1-EB96F4886707Q43768745-1358BA4C-5CF9-4798-ADC3-EBC7EB074E60Q47846912-08CBAD4A-1867-4849-A20A-0F6E33923AE0Q48204464-4CFE772D-CA6D-4696-A31D-9AA4371F71C0Q48212826-798A00FC-137F-4371-9AAF-032AFB50DD82Q48288388-6CECEA2F-0AE9-4E06-A1B2-C2BF9EC424E1Q48564640-16A2DB29-B773-4865-AFDC-C005B68F6B91Q49971623-15DA9D0F-DC73-4572-9DA0-916228B0124BQ50550439-DD1A51E4-5E49-4B37-B028-E679B6E35660Q52964689-D82D2810-A896-44C4-A181-759E6F40C818Q52990685-3665B67B-24A8-445C-9708-7A3040854FE0Q56373883-36A15494-1BA8-44A5-95A3-A92B40687080Q61809265-A9AB6F1A-16FB-4944-B6DA-4701304524DBQ88756002-6419B016-A34C-4ECD-A915-F1886DCF84CAQ88875107-31152CB4-CD28-4265-9209-1E40450F4961Q89992761-D0761707-310D-4DFF-A5CD-AB0894258257Q90080315-F78D46BA-7E89-479C-9CF8-2434309D82DFQ90225146-2F77B218-D36F-4C99-8DA1-88037D883B8CQ90263141-1EB1B716-7D75-4466-BDF4-919A36574F16Q90428718-2FFE7250-B241-4F00-8DD7-43277C5F5897Q90603865-CD67E3F9-F116-41C7-A3AE-64D28A27A0CBQ90996830-4C631A2E-4477-411B-9127-A436A71E8E05Q91325696-C8E58A58-A9C0-4827-A940-F07248852973Q91841348-F16785E9-4E9A-4931-8A34-6FF91E4BAD90Q92311462-4EF0AAB7-30B9-481D-8992-54CFA1BE0C25Q92342612-E1789158-3856-40EF-8ED5-679EFE67B10DQ92799004-BC4BCEAE-AC22-43F4-A2F6-667B3A5E9BF4
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Pierpaolo Alongi
@ast
Pierpaolo Alongi
@en
Pierpaolo Alongi
@es
Pierpaolo Alongi
@nl
Pierpaolo Alongi
@sl
type
label
Pierpaolo Alongi
@ast
Pierpaolo Alongi
@en
Pierpaolo Alongi
@es
Pierpaolo Alongi
@nl
Pierpaolo Alongi
@sl
prefLabel
Pierpaolo Alongi
@ast
Pierpaolo Alongi
@en
Pierpaolo Alongi
@es
Pierpaolo Alongi
@nl
Pierpaolo Alongi
@sl
P106
P1153
36192673100
P31
P496
0000-0002-8397-1640